Risankizumab (Skyrizi) is the first inhibitor of the p19 subunit of interleukin (IL) 23 approved for the treatment of moderate-to-severe Crohn's disease (CD). Although clinical trials and a few ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results